Pharmaceutical companies are not the only ones out to influence our practice of medicine. Experts, insurance reviewers, advocacy groups, hospital administrators and, of course, patients and their families are just some of the people who would like us to do things a certain way. How can we successfully manage this? Dr. Steven Dubovsky, the Chairman of the Department of Psychiatry at the University of Buffalo joins host Dr. Leslie Lundt to discuss strategies.
Managing the Influence of Others
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
Overview
Pharmaceutical companies are not the only ones out to influence our practice of medicine. Experts, insurance reviewers, advocacy groups, hospital administrators and, of course, patients and their families are just some of the people who would like us to do things a certain way. How can we successfully manage this? Dr. Steven Dubovsky, the Chairman of the Department of Psychiatry at the University of Buffalo joins host Dr. Leslie Lundt to discuss strategies.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Phase 3 study results of plozasiran in patients with FCS
Identifying the Great Imitator – Demystifying the Systemic Features of IgG4-Related Disease
IgG4-RD Case Conversations: Retroperitoneal Fibrosis with Refractory Ureteral Involvement
Biomarkers of the Storm: Decoding IRI’s Signature
HF Management for Patients with Comorbid Conditions
Analysis of Patients With and Without AF Living With HFmrEF/HFpEF: FINEARTS-HF
Effect of Finerenone on NT-proBNP in HFmrEF/HFpEF: FINEARTS-HF Trial
Kidney Risk Stratification in Finerenone Treatment: FINEARTS-HF Trial
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?